Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.
Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M.
Drug Des Devel Ther. 2023 Jun 26;17:1907-1932. doi: 10.2147/DDDT.S409373. eCollection 2023.
A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, Oikkonen J, Bulanova D, Pietras EJ, Voßgröne K, Chen YJ, Erkan EP, Dai J, Lundgren A, Grønning Høg MK, Larsen IM, Lamminen T, Kaipio K, Huvila J, Virtanen A, Engelholm L, Christiansen P, Santoni-Rugiu E, Huhtinen K, Carpén O, Hynninen J, Hautaniemi S, Vähärautio A, Wennerberg K.
Dev Cell. 2023 Jun 19;58(12):1106-1121.e7. doi: 10.1016/j.devcel.2023.04.012. Epub 2023 May 5.
Therapeutic potential of targeting mitochondrial dynamics in cancer.
Rodrigues T, Ferraz LS.
Biochem Pharmacol. 2020 Dec;182:114282. doi: 10.1016/j.bcp.2020.114282. Epub 2020 Oct 12.
Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors.
Wang X, Su S, Zhu Y, Cheng X, Cheng C, Chen L, Lei A, Zhang L, Xu Y, Ye D, Zhang Y, Li W, Zhang J.
Nat Commun. 2023 Sep 18;14(1):5778. doi: 10.1038/s41467-023-41470-9.
Androgens in women: Androgen-mediated skin disease and patient evaluation.
Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR.
J Am Acad Dermatol. 2019 Jun;80(6):1497-1506. doi: 10.1016/j.jaad.2018.08.062. Epub 2018 Oct 10.
Hyperandrogenism and Its Possible Effects on Endometrial Receptivity: A Review.
Yusuf ANM, Amri MF, Ugusman A, Hamid AA, Wahab NA, Mokhtar MH.
Int J Mol Sci. 2023 Jul 27;24(15):12026. doi: 10.3390/ijms241512026.
Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer.
Cao K, Zhang G, Yang M, Wang Y, He M, Zhang C, Huang Y, Lu J, Liu H.
Cancer Res. 2023 Jul 5;83(13):2171-2186. doi: 10.1158/0008-5472.CAN-22-3260.
Endometriosis-associated Malignancy.
Krawczyk N, Banys-Paluchowski M, Schmidt D, Ulrich U, Fehm T.
Geburtshilfe Frauenheilkd. 2016 Feb;76(2):176-181. doi: 10.1055/s-0035-1558239.
The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH, Seow KM, Chen KH.
Int J Mol Sci. 2022 Jul 23;23(15):8125. doi: 10.3390/ijms23158125.
Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S, Elayapillai SP, Qu D, Pitts K, Filatenkov A, Houchen CW, Berry WL, Moxley K, Hannafon BN.
Cancer Lett. 2023 Dec 1;578:216437. doi: 10.1016/j.canlet.2023.216437. Epub 2023 Oct 12.
